Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies

Yosuke Minami, Hironobu Minami, Toshihiro Miyamoto, Goichi Yoshimoto, Yukio Kobayashi, Wataru Munakata, Yasushi Onishi, Masahiro Kobayashi, Mari Ikuta, Geoffrey Chan, Adrian Woolfson, Chiho Ono, Mohammed Naveed Shaik, Yosuke Fujii, Xianxian Zheng, Tomoki Naoe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The hedgehog signaling pathway regulates multiple morphogenetic processes during embryogenesis. Aberrant activation of the hedgehog pathway signal transduction in adult tissues is associated with the pathogenesis of hematologic malignancies and solid tumors. We report findings from an open-label, multicenter phase I trial of the selective, small-molecule hedgehog signaling inhibitor glasdegib (PF-04449913) in Japanese patients with select advanced hematologic malignancies. Glasdegib was administered as once-daily oral doses (25, 50 and 100 mg) in 28-day cycles after a lead-in dose on Day −5. The primary objectives were to determine first-cycle dose-limiting toxicities, safety, vital signs and laboratory test abnormalities. Secondary objectives included evaluation of pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity of glasdegib. No dose-limiting toxicities were noted in the 13 patients in the present study. All patients experienced at least one treatment-emergent, all-causality adverse event. The most frequent treatment-related adverse events (observed in ≥3 patients) were dysgeusia (n = 9), muscle spasms (n = 5), alopecia, decreased appetite (n = 4 each), and increased blood creatinine phosphokinase, constipation and diarrhea (n = 3 each). Two deaths occurred during the study and were deemed not to be treatment-related due to disease progression. Glasdegib demonstrated dose-proportional pharmacokinetics, marked downregulation of the glioma-associated transcriptional regulator GLI1 expression in normal skin, and evidence of preliminary clinical activity, although data are limited. Glasdegib was safe and well tolerated across the dose levels tested. It is confirmed that the 100-mg dose is safe and tolerable in Japanese patients, and this dose level will be examined in the future clinical trial.

Original languageEnglish
Pages (from-to)1628-1633
Number of pages6
JournalCancer Science
Volume108
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Hematologic Neoplasms
Pharmacokinetics
Dysgeusia
Vital Signs
Alopecia
Spasm
Appetite
Constipation
Glioma
Causality
Embryonic Development
Disease Progression
Diarrhea
Signal Transduction
Creatinine
Phosphotransferases
Therapeutics
Down-Regulation
Clinical Trials
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies. / Minami, Yosuke; Minami, Hironobu; Miyamoto, Toshihiro; Yoshimoto, Goichi; Kobayashi, Yukio; Munakata, Wataru; Onishi, Yasushi; Kobayashi, Masahiro; Ikuta, Mari; Chan, Geoffrey; Woolfson, Adrian; Ono, Chiho; Shaik, Mohammed Naveed; Fujii, Yosuke; Zheng, Xianxian; Naoe, Tomoki.

In: Cancer Science, Vol. 108, No. 8, 01.08.2017, p. 1628-1633.

Research output: Contribution to journalArticle

Minami, Y, Minami, H, Miyamoto, T, Yoshimoto, G, Kobayashi, Y, Munakata, W, Onishi, Y, Kobayashi, M, Ikuta, M, Chan, G, Woolfson, A, Ono, C, Shaik, MN, Fujii, Y, Zheng, X & Naoe, T 2017, 'Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies', Cancer Science, vol. 108, no. 8, pp. 1628-1633. https://doi.org/10.1111/cas.13285
Minami, Yosuke ; Minami, Hironobu ; Miyamoto, Toshihiro ; Yoshimoto, Goichi ; Kobayashi, Yukio ; Munakata, Wataru ; Onishi, Yasushi ; Kobayashi, Masahiro ; Ikuta, Mari ; Chan, Geoffrey ; Woolfson, Adrian ; Ono, Chiho ; Shaik, Mohammed Naveed ; Fujii, Yosuke ; Zheng, Xianxian ; Naoe, Tomoki. / Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies. In: Cancer Science. 2017 ; Vol. 108, No. 8. pp. 1628-1633.
@article{4baa93d20beb4c3ab12008450ed3a414,
title = "Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies",
abstract = "The hedgehog signaling pathway regulates multiple morphogenetic processes during embryogenesis. Aberrant activation of the hedgehog pathway signal transduction in adult tissues is associated with the pathogenesis of hematologic malignancies and solid tumors. We report findings from an open-label, multicenter phase I trial of the selective, small-molecule hedgehog signaling inhibitor glasdegib (PF-04449913) in Japanese patients with select advanced hematologic malignancies. Glasdegib was administered as once-daily oral doses (25, 50 and 100 mg) in 28-day cycles after a lead-in dose on Day −5. The primary objectives were to determine first-cycle dose-limiting toxicities, safety, vital signs and laboratory test abnormalities. Secondary objectives included evaluation of pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity of glasdegib. No dose-limiting toxicities were noted in the 13 patients in the present study. All patients experienced at least one treatment-emergent, all-causality adverse event. The most frequent treatment-related adverse events (observed in ≥3 patients) were dysgeusia (n = 9), muscle spasms (n = 5), alopecia, decreased appetite (n = 4 each), and increased blood creatinine phosphokinase, constipation and diarrhea (n = 3 each). Two deaths occurred during the study and were deemed not to be treatment-related due to disease progression. Glasdegib demonstrated dose-proportional pharmacokinetics, marked downregulation of the glioma-associated transcriptional regulator GLI1 expression in normal skin, and evidence of preliminary clinical activity, although data are limited. Glasdegib was safe and well tolerated across the dose levels tested. It is confirmed that the 100-mg dose is safe and tolerable in Japanese patients, and this dose level will be examined in the future clinical trial.",
author = "Yosuke Minami and Hironobu Minami and Toshihiro Miyamoto and Goichi Yoshimoto and Yukio Kobayashi and Wataru Munakata and Yasushi Onishi and Masahiro Kobayashi and Mari Ikuta and Geoffrey Chan and Adrian Woolfson and Chiho Ono and Shaik, {Mohammed Naveed} and Yosuke Fujii and Xianxian Zheng and Tomoki Naoe",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/cas.13285",
language = "English",
volume = "108",
pages = "1628--1633",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies

AU - Minami, Yosuke

AU - Minami, Hironobu

AU - Miyamoto, Toshihiro

AU - Yoshimoto, Goichi

AU - Kobayashi, Yukio

AU - Munakata, Wataru

AU - Onishi, Yasushi

AU - Kobayashi, Masahiro

AU - Ikuta, Mari

AU - Chan, Geoffrey

AU - Woolfson, Adrian

AU - Ono, Chiho

AU - Shaik, Mohammed Naveed

AU - Fujii, Yosuke

AU - Zheng, Xianxian

AU - Naoe, Tomoki

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The hedgehog signaling pathway regulates multiple morphogenetic processes during embryogenesis. Aberrant activation of the hedgehog pathway signal transduction in adult tissues is associated with the pathogenesis of hematologic malignancies and solid tumors. We report findings from an open-label, multicenter phase I trial of the selective, small-molecule hedgehog signaling inhibitor glasdegib (PF-04449913) in Japanese patients with select advanced hematologic malignancies. Glasdegib was administered as once-daily oral doses (25, 50 and 100 mg) in 28-day cycles after a lead-in dose on Day −5. The primary objectives were to determine first-cycle dose-limiting toxicities, safety, vital signs and laboratory test abnormalities. Secondary objectives included evaluation of pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity of glasdegib. No dose-limiting toxicities were noted in the 13 patients in the present study. All patients experienced at least one treatment-emergent, all-causality adverse event. The most frequent treatment-related adverse events (observed in ≥3 patients) were dysgeusia (n = 9), muscle spasms (n = 5), alopecia, decreased appetite (n = 4 each), and increased blood creatinine phosphokinase, constipation and diarrhea (n = 3 each). Two deaths occurred during the study and were deemed not to be treatment-related due to disease progression. Glasdegib demonstrated dose-proportional pharmacokinetics, marked downregulation of the glioma-associated transcriptional regulator GLI1 expression in normal skin, and evidence of preliminary clinical activity, although data are limited. Glasdegib was safe and well tolerated across the dose levels tested. It is confirmed that the 100-mg dose is safe and tolerable in Japanese patients, and this dose level will be examined in the future clinical trial.

AB - The hedgehog signaling pathway regulates multiple morphogenetic processes during embryogenesis. Aberrant activation of the hedgehog pathway signal transduction in adult tissues is associated with the pathogenesis of hematologic malignancies and solid tumors. We report findings from an open-label, multicenter phase I trial of the selective, small-molecule hedgehog signaling inhibitor glasdegib (PF-04449913) in Japanese patients with select advanced hematologic malignancies. Glasdegib was administered as once-daily oral doses (25, 50 and 100 mg) in 28-day cycles after a lead-in dose on Day −5. The primary objectives were to determine first-cycle dose-limiting toxicities, safety, vital signs and laboratory test abnormalities. Secondary objectives included evaluation of pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity of glasdegib. No dose-limiting toxicities were noted in the 13 patients in the present study. All patients experienced at least one treatment-emergent, all-causality adverse event. The most frequent treatment-related adverse events (observed in ≥3 patients) were dysgeusia (n = 9), muscle spasms (n = 5), alopecia, decreased appetite (n = 4 each), and increased blood creatinine phosphokinase, constipation and diarrhea (n = 3 each). Two deaths occurred during the study and were deemed not to be treatment-related due to disease progression. Glasdegib demonstrated dose-proportional pharmacokinetics, marked downregulation of the glioma-associated transcriptional regulator GLI1 expression in normal skin, and evidence of preliminary clinical activity, although data are limited. Glasdegib was safe and well tolerated across the dose levels tested. It is confirmed that the 100-mg dose is safe and tolerable in Japanese patients, and this dose level will be examined in the future clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=85020539106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020539106&partnerID=8YFLogxK

U2 - 10.1111/cas.13285

DO - 10.1111/cas.13285

M3 - Article

C2 - 28556364

AN - SCOPUS:85020539106

VL - 108

SP - 1628

EP - 1633

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -